Forecast

There is no analyst data available for this company.

News Go to news feed

Ambu share falls 15% after slightly missed quarter

Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » More on de.investing.com
Ambu forecasts significant quarterly growth in EPS and revenue

Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » More on finanzen.net
Ambu confirms outlook after Q1 – endoscopy growth offsets currency and tariff headwinds

Ambu reported organic revenue growth of 8.6% in Q1 2025/26 (reported 3.2% after currency impact) and total revenue of DKK 1,558m. The driver was the Endoscopy Solutions segment with 14.4% organic growth; Anesthesia & Patient Monitoring was flat. EBIT margin before special items fell to 10.5%; adjusted for tariffs and currency effects it would be 15.2%. Free cash flow was DKK 13m. Ambu confirmed its full-year outlook of 10–13% organic revenue growth and a target EBIT margin of 12–14%, but continued to see currency and tariff risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Ambu has already paid 0,0549€ in dividends. The last payout was in December 2025.

Financials

In the last quarter, Ambu had revenue of 210.70m€ and net profit of 16.21m€

(EUR)	Mar 2026	YoY
Revenue	+210.70m	1,15%
Gross profit	+126.98m	0,57%
Net profit	+16.21m	35,68%
EBITDA	+36.30m	15,90%

Fundamentals

Metric	Value
Market capitalization	+2.24b€
Number of shares	263.04m
52-week high/low	+13,23€ - +8,07€
Dividend yield	+0,63%
Dividends TTM	+0,0549€
Beta	1,3
P/E ratio	+44,04
PEG ratio	+1,52
P/B ratio	+3,43
P/S ratio	+3,41

Company profile

Ambu A/S entwickelt, produziert und vertreibt medizinische Geräte für Krankenhäuser, Kliniken und Rettungsdienste weltweit. Das Unternehmen bietet Gesundheitslösungen in den Bereichen Visualisierung, Anästhesie, Patientenüberwachung und Diagnostik. Das Unternehmen bietet Produkte für die Endoskopie, wie Bronchoskope und Monitore, und Produkte für die Neurologie, wie EEG- und EMG-Elektroden, EMG-geführte Injektionen und intraoperative Überwachungsprodukte. Darüber hinaus bietet das Unternehmen Produkte für die Kardiologie, bestehend aus EKG-Elektroden, sowie Produkte für das Atemwegsmanagement und die Anästhesie, wie Bronchoskope, Videolaryngoskope, doppel- und einlumige Tuben, endobronchiale Blocker, Kehlkopf- und Gesichtsmasken, Beatmungsbeutel und Wiederbelebungsgeräte. Darüber hinaus bietet das Unternehmen Befreiungsmanschetten, Kopf-Immobilizer, CPR-Atembarrieren und Übungspuppen an. Ambu A/S wurde 1937 gegründet und hat seinen Hauptsitz in Ballerup, Dänemark.

Name	Ambu
CEO	Britt Meelby Jensen
Headquarters	Ballerup, cr Denmark
Website	ambu.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	02/11/2004
Employees	5.384